Integrated multi-omics revealed that dysregulated lipid metabolism played an important role in RA patients with metabolic diseases.
Lipid metabolism
Metabolic diseases
Multi-omics
Rheumatoid arthritis
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
01 Nov 2024
01 Nov 2024
Historique:
received:
17
07
2024
accepted:
22
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Patients with rheumatoid arthritis (RA) commonly experience a high prevalence of multiple metabolic diseases (MD), leading to higher morbidity and premature mortality. Here, we aimed to investigate the pathogenesis of MD in RA patients (RA_MD) through an integrated multi-omics approach. Fecal and blood samples were collected from a total of 181 subjects in this study for multi-omics analyses, including 16S rRNA and internally transcribed spacer (ITS) gene sequencing, metabolomics, transcriptomics, proteomics and phosphoproteomics. Spearman's correlation and protein-protein interaction networks were used to assess the multi-omics data correlations. The Least Absolute Shrinkage and Selection Operator (LASSO) machine learning algorithm were used to identify disease-specific biomarkers for RA_MD diagnosis. Our results found that RA_MD was associated with differential abundance of gut microbiota such as Turicibacter and Neocosmospora, metabolites including decreased unsaturated fatty acid, genes related to linoleic acid metabolism and arachidonic acid metabolism, as well as downregulation of proteins and phosphoproteins involved in cholesterol metabolism. Furthermore, a multi-omics classifier differentiated RA_MD from RA with high accuracy (AUC: 0.958). Compared to gouty arthritis and systemic lupus erythematosus, dysregulation of lipid metabolism showed disease-specificity in RA_MD. The integration of multi-omics data demonstrates that lipid metabolic pathways play a crucial role in RA_MD, providing the basis and direction for the prevention and early diagnosis of MD, as well as new insights to complement clinical treatment options.
Identifiants
pubmed: 39482717
doi: 10.1186/s13075-024-03423-5
pii: 10.1186/s13075-024-03423-5
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
188Subventions
Organisme : Administration of Traditional Chinese Medicine of Sichuan Province
ID : 2023MS640
Organisme : Administration of Traditional Chinese Medicine of Sichuan Province
ID : 2023MS640
Organisme : Key Projects fund of the Science & Technology Department of Sichuan Province
ID : 2021YFS0165,2022JDRC0069,22MZGC0090
Organisme : the Health Commission of Sichuan Province
ID : 21PJ085
Organisme : Innovative Scientific Research Project of Medical in Sichuan Province
ID : S20001
Informations de copyright
© 2024. The Author(s).
Références
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.
Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36(3):182–8.
Nicolau J, et al. Rheumatoid arthritis, insulin resistance, and diabetes. Joint Bone Spine. 2017;84(4):411–6.
Del Rincon I, et al. Acceleration of atherosclerosis during the course of rheumatoid arthritis. Atherosclerosis. 2007;195(2):354–60.
Adawi M, Firas S, Blum A. Rheumatoid arthritis and atherosclerosis. Isr Med Assoc J. 2019;21(7):460–3.
Radner H, et al. Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arthritis Care Res. 2017;69(10):1510–8.
Pereira RM, de Carvalho JF, Bonfa E. Metabolic syndrome in rheumatological diseases. Autoimmun Rev. 2009;8(5):415–9.
Medina G, et al. Metabolic syndrome, autoimmunity and rheumatic diseases. Pharmacol Res. 2018;133:277–88.
Chen Y, et al. Association of Cardiovascular Disease with premature mortality in the United States. JAMA Cardiol. 2019;4(12):1230–8.
Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol. 2003;30(1):36–40.
Kasperova S, et al. Rheumatoid arthritis and metabolic disorders. Vnitr Lek. 2021;67(E–2):18–24.
He J, Jia Y. Application of omics technologies in dermatological research and skin management. J Cosmet Dermatol. 2022;21(2):451–60.
Zhang Q, et al. Integrative analysis of multi-omics data to detect the underlying molecular mechanisms for obesity in vivo in humans. Hum Genomics. 2022;16(1):15.
Chen C, Wang J, Pan D, et al. Applications of multi-omics analysis in human diseases. MedComm. 2023;4(4):e315.
Mars RAT, et al. Longitudinal multi-omics reveals subset-specific mechanisms underlying irritable bowel syndrome. Cell. 2020;182(6):1460–e147317.
Wang Y, et al. Rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren’s syndrome shared megakaryocyte expansion in peripheral blood. Ann Rheum Dis. 2022;81(3):379–85.
Baker JF, et al. Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis. Ann Rheum Dis. 2021;80(5):566–72.
Costello RE, et al. The effect of glucocorticoid therapy on mortality in patients with rheumatoid arthritis and concomitant type II diabetes: a retrospective cohort study. BMC Rheumatol. 2020;4:4.
Aletaha D, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8.
Neogi T, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol 2015;67(10):2557–68.
Chen J, et al. Multi-omics profiling reveals potential alterations in rheumatoid arthritis with different disease activity levels. Arthritis Res Ther. 2023;25(1):74.
Jian C, et al. Comprehensive multi-omics analysis reveals the core role of glycerophospholipid metabolism in rheumatoid arthritis development. Arthritis Res Ther. 2023;25(1):246.
Zhu J, et al. The change of plasma metabolic profile and gut microbiome dysbiosis in patients with rheumatoid arthritis. Front Microbiol. 2022;13:931431.
Zhang X, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med. 2015;21(8):895–905.
Horta-Baas G, et al. Intestinal dysbiosis and rheumatoid arthritis: a link between Gut Microbiota and the pathogenesis of rheumatoid arthritis. J Immunol Res. 2017;2017:p4835189.
Lee EH, et al. Dysbiotic but nonpathogenic shift in the fecal mycobiota of patients with rheumatoid arthritis. Gut Microbes. 2022;14(1):2149020.
Wang Y, et al. Gut dysbiosis in rheumatic diseases: a systematic review and meta-analysis of 92 observational studies. EBioMedicine. 2022;80:104055.
Wei Y, et al. Alterations of gut microbiome in autoimmune hepatitis. Gut. 2020;69(3):569–77.
Salem F, et al. Gut microbiome in chronic rheumatic and inflammatory bowel diseases: similarities and differences. United Eur Gastroenterol J. 2019;7(8):1008–32.
Liu H, et al. Alterations of gut microbiota and blood lipidome in gestational diabetes mellitus with hyperlipidemia. Front Physiol. 2019;10:1015.
Dong Y, et al. Characterization of gut microbiota in adults with coronary atherosclerosis. PeerJ. 2023;11:e15245.
Bodkhe R, Balakrishnan B, Taneja V. The role of microbiome in rheumatoid arthritis treatment. Ther Adv Musculoskelet Dis. 2019;11:1759720X19844632.
Lynch JB, et al. Gut microbiota Turicibacter strains differentially modify bile acids and host lipids. Nat Commun. 2023;14(1):3669.
Liu S, et al. Effects of lipid extract from blue mussel (Mytilus edulis) on gut microbiota, and its relationship with glycemic traits in type 2 diabetes mellitus patients: a double-blind randomized controlled trial. Food Funct. 2023;14(19):8922–32.
Harris DM, et al. Tryptophan degradation as a systems phenomenon in inflammation–an analysis across 13 chronic inflammatory diseases. Ebiomedicine. 2024;102:105056
Takada A, et al. Plasma levels of tryptophan metabolites in patients of type 2 diabetes mellitus. In: Watson RR, Preedy VR, editors. Bioactive food as dietary interventions for diabetes. Academic Press; 2019. p. 265–276.
Hajishafiee M, et al. Effects of intragastric administration of L-tryptophan on the glycaemic response to a nutrient drink in men with type 2 diabetes—impacts on gastric emptying, glucoregulatory hormones and glucose absorption. Nutr Diabetes. 2021;11(1):3.
Kien CL, et al. Lipidomic evidence that lowering the typical dietary palmitate to oleate ratio in humans decreases the leukocyte production of proinflammatory cytokines and muscle expression of redox-sensitive genes. J Nutr Biochem. 2015;26(12):1599–606.
Das UN. Pro- and anti-inflammatory bioactive lipids imbalance contributes to the pathobiology of autoimmune diseases. Eur J Clin Nutr. 2023;77(6):637–51.
Olson MV, et al. Docosahexaenoic acid reduces inflammation and joint destruction in mice with collagen-induced arthritis. Inflamm Res. 2013;62(12):1003–13.
Calder PC. The role of marine omega‐3 (n‐3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Mol Nutr Food Res. 2012;56(7):1073–80.
Kelley DS, Adkins S. Similarities and differences between the effects of EPA and DHA on markers of atherosclerosis. Hum Subj. 2012;71(2):322–31.
Mustonen AM, et al. Increased n-6 polyunsaturated fatty acids indicate Pro- and anti-inflammatory lipid modifications in synovial membranes with rheumatoid arthritis. Inflammation. 2023;46(4):1396–413.
Tański W, et al. The relationship between fatty acids and the development, course and treatment of rheumatoid arthritis. Nutrients. 2022;14(5):1030.
Wang W, et al. Effects of omega-3 supplementation on lipid metabolism, inflammation, and disease activity in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Clin Rheumatol. 2024;43(8):2479–88.
Lu J, et al. Impact of omega-3 fatty acids on hypertriglyceridemia, lipidomics, and gut microbiome in patients with type 2 diabetes. Med. 2024. https://doi.org/10.1016/j.medj.2024.07.024 .
Schuchardt JP, et al. Higher docosahexaenoic acid proportions in blood are inversely associated with the prevalence of pre-diabetes: evidence from the UK biobank. Nutr Res. 2024;131:62–70.
Harris K, et al. Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study. Diabetologia. 2020;63:1637–47.
Duan Y, et al. Hepatic cholesterol accumulation ascribed to the activation of ileum Fxr-Fgf15 pathway inhibiting hepatic Cyp7a1 in high-fat diet-induced obesity rats. Life Sci. 2019;232:116638.
Yan J, et al. Dyslipidemia in rheumatoid arthritis: the possible mechanisms. Front Immunol. 2023;14:1254753.
de Vries R, et al. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes. 2005;54(12):3554–9.
Boekholdt SM, et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)–Norfolk population study. Circulation. 2004;110(11):1418–23.
Daïen CI, et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis. 2012;71(6):862–8.
Georgiadis AN, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment–a prospective, controlled study. Arthritis Res Ther. 2006;8:1–7.